Some studies have revealed COX-2 is overexpressed in many malignant tumors such as HCC and the selective COX-2 inhibitor markedly inhibited the growth of HCC cell in vitro and in vivo [6–8]. This evidence concerns the gene PTGS2 and hepatocellular carcinoma.